COVID-19: Steps towards the vaccine

A Statista DossierPlus on viral diseases and vaccines, with a focus on COVID19 phase-out scenarios

COVID-19: Steps towards the vaccine The outbreaks of viral diseases have shaped human history, being a recurring phenomenon in all human societies of all times. Since the 18th century, vaccines have been playing a pivotal role in contrasting the spread of viral diseases and pushing some of them towards their complete eradication.

Since March 2020, the world has been facing the COVID-19 pandemic caused by the SARS-CoV-2 virus that, as of mid-December 2020, has caused over 1.5 million casualties worldwide. The deep impact of the COVID-19 pandemic has triggered an unprecedented international response for its handling and containment, with a strong emphasis on the timely development of a vaccine that resulted, in less than one year, in more than ten candidate vaccines being in the last stage of clinical trials.
Once there will be one (or multiple) vaccines for COVID-19, how will their production and global distribution be organized and managed? This DossierPlus presents three scenarios for the COVID-19 vaccine’s production: Whereas in two of them the herd immunity is approached over two years after the vaccine starts to be distributed, the immunization of the global elderly population and workers in the healthcare systems appears attainable within one year.

For further insights on the development of the COVID-19 vaccination campaign, check our COVID-19: vaccination status quo DossierPlus!
DescriptionContent

The pandemic outbreak of COVID-19 is leaving a mark on the 21st century, in a similar fashion as notorious outbreaks of poliomyelitis, smallpox, measles, the so-called Spanish flu, and AIDS have shaped (and is still shaping, for the latter) their times.
The past four decades have seen declining numbers of infections for those viral diseases for which a vaccine is available, like measles and poliomyelitis. Smallpox was even completely eradicated in 1980, as a result of globally coordinated mass-vaccination campaigns.
As several vaccines for COVID-19 are in their latest stage of clinical testing and the release of one (or more) of them appears as very likely by the first quarter of 2021, the question is how and how fast the vaccine will contrast the pandemic spread of the SARS-CoV-2 virus.

For a deeper insight, download our COVID-19: steps towards the vaccine DossierPlus.

More than 7,500
companies
trust
Statista
Recommended studies and dossiers
Show more
Recent studies and dossiers
You may also be interested in...
Statista is a great source of knowledge, and pretty helpful to manage the daily work.

Christof Baron about Statista CEO, MindShare Germany

Any more questions?

Get in touch with us quickly and easily.
We are happy to help!